Cholesterol and Cancer: From Danger Signal to Treatment Target

Table of Contents

• Key Points
• Why This Research Matters: Cholesterol Is Not Just a Heart Problem
• How This Study Was Conducted: A Research Review
• Understanding Cholesterol Metabolism: The Basics
• How Cancer Cells Build New Cholesterol
• How Cancer Cells Take In Cholesterol From Outside
• How Cells Release and Store Cholesterol
• Oxysterols: Cholesterol's Powerful Chemical Relatives
• How Cancer Rewires Cholesterol Regulation
• The p53 Gene: A Double Agent in Cholesterol Control
• The Tumor Microenvironment: A Hostile Neighborhood
• Noncoding RNAs: Tiny Managers of Cholesterol Genes
• Clinical Implications: Targeting Cholesterol to Treat Cancer
• Limitations of This Review
• What This Means for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Cancer cells often lose normal cholesterol balance, increasing uptake and synthesis to support tumor growth and spread.
• Cholesterol metabolism is regulated by SREBP proteins, and cancers frequently activate this pathway through mutations or tumor environment signals.
• Normal p53 suppresses cholesterol production, while mutant p53 promotes it, creating a feedback loop that may drive cancer growth.
• Drugs targeting cholesterol metabolism, such as statins and ACAT1 inhibitors, are being studied as potential cancer therapies in laboratory models.
• Cholesterol's effect on cancer depends on cancer type and genetic context, so personalized treatment approaches would be needed.

Why This Research Matters: Cholesterol Is Not Just a Heart Problem

Most people associate cholesterol with heart disease and clogged arteries. But cholesterol plays a far bigger role in the body than that. Cells use cholesterol as an essential building block for their outer membranes — the protective barrier that keeps each cell intact and functional. Cholesterol contributes directly to membrane integrity and fluidity, meaning it helps membranes stay strong yet flexible.

Cholesterol is also a precursor (starting material) for bile acids and steroid hormones. In other words, without cholesterol, the body could not digest fats properly or produce key hormones.

Here is the cancer connection: cells that become cancerous lose control of cholesterol balance. In cancer cells, cholesterol uptake and synthesis rates are usually increased, leading to abnormal metabolism. This is so consistent that scientists now describe cholesterol dyshomeostasis — the loss of normal cholesterol balance — as one of the hallmarks of cancer.

Cholesterol does not just sit in membranes. It affects many fundamental cancer behaviors, including the immune response, ferroptosis (a form of iron-dependent cell death), autophagy (cellular recycling), cell stemness (the ability of cells to self-renew), and the DNA damage response (the cell's ability to repair broken DNA).

Because cholesterol metabolism plays such a central role in tumor formation and progression, scientists are now targeting this pathway as a new direction in cancer treatment. This review article brings together recent findings on how cholesterol metabolism works in cancer cells and how drugs that block cholesterol processing might become part of cancer therapy.

How This Study Was Conducted: A Research Review

This article is not a single experiment with patients. It is a review article published in Experimental & Molecular Medicine. The research team, led by Dr. Xianjun Yu and Dr. Si Shi at Fudan University Shanghai Cancer Center in China, systematically gathered and analyzed recent scientific literature on cholesterol metabolism in cancer.

The authors examined published studies describing cholesterol metabolism pathways in cancer cells. They focused on how cancer progression and cholesterol metabolism regulate each other. They also reviewed evidence on various drugs that target cholesterol metabolism.

The review includes evidence from laboratory studies, animal models (such as mice with SR-BI mutations), and cell studies of many cancer types, including breast, pancreatic, prostate, glioblastoma, lung, gastric, endometrial, liver, and ovarian cancers. Because it is a review, the conclusions come from combining many separate research findings rather than following one group of patients.

Understanding Cholesterol Metabolism: The Basics

Cholesterol metabolism involves four major processes. They are synthesis (building new cholesterol), uptake (bringing cholesterol into the cell), efflux (pushing cholesterol out of the cell), and esterification (storing cholesterol in a modified form called cholesteryl esters). All four processes are altered in cancer cells.

Many cholesterol-related genes are controlled by a key regulatory system. The system centers on proteins called SREBPs (sterol regulatory element binding proteins). These are transcription factors — proteins that turn genes on — and they play central roles in controlling cholesterol manufacture. SREBPs belong to a protein family characterized by a "basic helix-loop-helix-leucine zipper" (bHLH-Zip) motif, a specific structural pattern that allows them to attach to DNA.

Three members of the SREBP family exist: SREBP-1a, SREBP-1c, and SREBP-2. SREBP-1a and SREBP-1c mainly regulate enzymes involved in fatty acid, triglyceride, and glucose metabolism. SREBP-2 mainly regulates cholesterol metabolism.

How Cancer Cells Build New Cholesterol

Cells can manufacture their own cholesterol from scratch. This process is called de novo cholesterol biosynthesis, and it runs through the mevalonate pathway. The entire process is extremely complex, involving about 30 separate reactions.

Here is how the assembly line works, step by step:

1. The starting material is acetyl-CoA (acetyl coenzyme A), a molecule produced from nutrients.
2. Two molecules of acetyl-CoA are condensed into acetoacetyl-CoA. An enzyme called cytosolic thiolase catalyzes this reaction.
3. Acetoacetyl-CoA combines with another acetyl-CoA molecule. HMG-CoA synthase catalyzes this step, producing HMG-CoA (3-hydroxy-3-methylglutaryl-CoA).
4. HMG-CoA reductase (HMGCR) converts HMG-CoA into mevalonic acid (MVA). HMGCR is the primary rate-limiting enzyme, meaning it is the main bottleneck controlling how fast cholesterol is made. This step consumes two NADPH molecules (cellular energy carriers).
5. MVA undergoes a three-step enzymatic reaction involving phosphorylation and decarboxylation. The result is isopentenyl pyrophosphate (IPP).
6. A series of enzymatic reactions in the cytoplasm converts IPP into farnesyl pyrophosphate (FPP).
7. Two molecules of FPP condense into squalene. The enzyme squalene synthase catalyzes this reaction.
8. Squalene is oxidized to 2,3-epoxysqualene by squalene epoxidase (SQLE).
9. The molecule is then cyclized to lanosterol.
10. Lanosterol is finally converted to cholesterol through complex reactions in the endoplasmic reticulum (ER), the cell's protein and lipid factory.

These biosynthetic processes are energy-consuming. They depend on ATP and NADPH, the cell's main energy currencies. This is one reason cancer cells with high energy demands often ramp up cholesterol production.

Newly synthesized cholesterol in the ER is transported directly or indirectly to the cell membrane through the Golgi apparatus, another cellular processing center.

The On-Off Switch for Cholesterol Genes

SREBP-2 is synthesized in the ER as a nonfunctional precursor. It forms a complex with a partner protein called SCAP (SREBP cleavage-activating protein). Together, SREBP-2 and SCAP coregulate intracellular cholesterol levels.

When cholesterol is needed, SREBP-2 must travel from the ER to the Golgi apparatus. There, two enzymes called site 1 protease (S1P) and site 2 protease (S2P) cut it free from the membrane. After this sequential processing, SREBP-2 loses its anchor and releases an active fragment containing the bHLH-Zip region. The processed SREBP2 enters the nucleus as a homodimer (a pair of identical units). There it attaches to the sterol regulatory element (SRE) sequence in the promoters of target genes — including HMGCR and SQLE, the genes encoding two key cholesterol-building enzymes. This activates gene transcription, meaning the cell starts building new cholesterol machinery.

High cholesterol in the ER stops this process. Cholesterol and certain related molecules bind to a protein called Insig, which holds the SCAP-SREBP2 complex in the ER, preventing its travel to the Golgi.

How Cancer Cells Take In Cholesterol From Outside

Cells do not rely only on making their own cholesterol. They also import it from the bloodstream. Two main pathways bring outside cholesterol into cells.

The first is low-density lipoprotein (LDL) uptake. LDL particles — sometimes called "bad cholesterol" — bind to LDL receptors (LDLR) on the cell membrane. The LDL receptor then pulls the particle inside through endocytosis, a process where the membrane wraps around the particle to form an internal bubble. The particle eventually reaches the lysosome, the cell's recycling compartment. There, acid lipase hydrolyzes (breaks down) the contents, releasing free cholesterol. LDL receptor-mediated endocytosis is the most important mechanism for clearing cholesterol from the blood plasma.

The second pathway involves high-density lipoprotein (HDL), sometimes called "good cholesterol." HDL cholesteryl esters enter cells through selective uptake. This process requires the HDL receptor SR-BI (scavenger receptor class B type I), a member of the class B family of scavenger receptors. SR-BI forms a lipophilic (fat-loving) channel in the plasma membrane. Through its extracellular domain, SR-BI binds to HDL cholesteryl esters and selectively delivers them into the cell.

SR-BI has a specific structure that matters for its function. The extracellular loop of SR-BI contains six highly conserved cysteine residues that are critical to SR-BI activity. Studies in mice show the importance of this receptor: mice with SR-BI mutations had increased plasma cholesterol levels. In addition, inhibition of SR-BI glycosylation (a process that adds sugar groups to proteins) led to defective selective uptake of HDL cholesteryl esters.

How Cells Release and Store Cholesterol

Cholesterol also leaves cells, and this release — called efflux — is the most important step in reverse cholesterol transport, the body's system for returning cholesterol from tissues back to the liver.

Here is the body-wide journey of dietary cholesterol. Cholesterol from food is absorbed in the gastrointestinal tract, where cholesterol and triglycerides (fats) form chylomicrons (fat-carrying particles). In the bloodstream, chylomicrons are modified into remnants that travel to the liver. In the liver, very low-density lipoprotein (VLDL) particles — containing lipids and cholesterol — are secreted by hepatocytes (liver cells). These particles are further modified into LDL in the blood circulation and then transported to peripheral cells. Excess cholesterol in peripheral cells is released as HDL cholesterol, triggering the reverse transport of cholesterol back to the liver.

Cells release cholesterol through four distinct mechanisms:

• Passive diffusion of cholesterol carried by mature HDL particles
• SR-B1-mediated facilitated diffusion
• ABCA1-mediated efflux, where the ATP-binding cassette transporter subfamily A member 1 (ABCA1) moves cholesterol out with the help of ApoA1 (apolipoprotein A1, the main protein in HDL)
• ABCG-mediated efflux, where ABC subfamily G transporters release cholesterol with mature HDL

Free cholesterol released from the plasma membrane undergoes passive aqueous diffusion driven by the cholesterol gradient. That gradient is maintained through esterification of HDL surface cholesterol by an enzyme called LCAT (lecithin–cholesterol acyltransferase).

Plasma contains not only free cholesterol but also esterified cholesterol — cholesterol chemically linked to a fatty acid. The conversion of cholesterol into cholesteryl esters is mediated by enzymes called ACATs (acyl-CoA: cholesterol acyltransferases). Two forms exist: ACAT1 and ACAT2. ACAT1 is expressed in most human tissue cells. Cholesteryl esters synthesized by ACAT1 are usually stored in lipid droplets (fat storage compartments inside cells). ACAT2, in contrast, shows development- and species-specific expression. ACAT2 is highly expressed in the human intestine and in the infant liver. Cholesteryl esters made by ACAT2 are mainly transported by lipoproteins, which can be secreted out of cells.

Studies have shown that ACAT-1 expression and activity are increased in breast, pancreatic, and glioblastoma (brain cancer) tumor cells, promoting cholesteryl ester production. This matters for cancer spread. Excessive cholesteryl ester production activates SREBP1, which promotes tumor metastasis (the spread of cancer to other parts of the body). The reverse is also true in experiments: inhibition of ACAT-1 production led to inhibited glioblastoma growth and reduced prostate cancer cell invasiveness.

Oxysterols: Cholesterol's Powerful Chemical Relatives

Beyond storage, cholesterol can be converted into oxysterols — oxygenated forms of cholesterol. These molecules are found in low or very low concentrations in the human body, mainly inside oxidized lipoproteins. Despite their low levels, oxysterols pack a strong biological punch. They modulate the fluidity of the cell membrane and exert other cellular functions, including signaling roles in cancer.

Oxysterols form through two routes. First, they can arise by autooxidation (spontaneous oxidation) in the presence of reactive oxygen species (ROS) — unstable molecules that can damage cells. Second, enzymes can produce them deliberately. Cholesterol oxygenation usually occurs on the steroid backbone (the rigid ring structure of cholesterol) or on the aliphatic side chain (a chain of carbon atoms attached to the rings).

Oxidation of the side chain generates several specific oxysterols:

• 27-hydroxycholesterol (27-HC)
• 25-hydroxycholesterol (25-HC)
• 24-hydroxycholesterol (24-HC)
• 22-hydroxycholesterol (22-HC)

Backbone oxidation generates a different set:

• 7-ketocholesterol (7-KC)
• 5,6α-epoxycholesterol and 5,6β-epoxycholesterol (5,6α-EC and 5,6β-EC)
• 7α-hydroxycholesterol and 7β-hydroxycholesterol (7α/β-HC)

Side chain oxysterol production is mainly mediated by enzymes of the cytochrome p450 (CYP) family. Specific enzymes handle specific conversions. CYP27A1 generates 27-HC, and CYP7B1 catabolizes it (breaks it down). CYP46A1 catalyzes cholesterol metabolism to yield 24(S)-HC. CYP11A1 generates 22(R)-HC. Notably, 25-HC is generated by cholesterol-25-hydroxylase — an enzyme outside the CYP family. In addition to these enzymatic routes, lipid peroxidation (oxidative damage to fats) indirectly generates oxysterols such as B-ring oxysterols.

Oxysterols at Work in the Body

Oxysterols act as natural signaling molecules. Several — including 22(R)-HC, 25-HC, 27-HC, and 24(S)-HC — modulate the activity of liver X receptors (LXRs), transcription factors that help maintain cholesterol balance. Oxysterols can also target other nuclear receptors, including RAR-related orphan receptors (RORs), estrogen receptors (ERs), and the glucocorticoid receptor (GR). Different oxysterols act as either agonists (activators) or inverse agonists (suppressors) of RORs, meaning they can push these receptors in opposite directions.

Specific examples from the research literature include:

• 27-HC functions as an agonist of RORγ, activating it.
• 24(S)-HC and 25-HC act as inverse agonists of RORα and RORγ, suppressing their activity.
• In a notable study, 25-HC and 22-HC restored RORγ transcriptional activity that had been suppressed by a synthetic inhibitor.
• 22(R)-HC, 24(S)-HC, 25-HC, 27-HC, and 7-KC regulate estrogen receptor activities.
• A molecule called OCDO (6-oxo-cholestan-3β,5α-diol), generated from 5,6-EC, has been identified as a glucocorticoid receptor ligand. OCDO also acts as a dual GR and LXR ligand.

27-HC deserves special attention. It is the most abundant oxysterol in the cell membrane and blood. Because of its structure, it easily crosses the blood–brain barrier. Scientists sometimes call it a "cerebrosterol" because of its presence in the brain. Increasing evidence links 27-HC to cancer, especially breast cancer. Studies have shown that 27-HC activates LXRs to promote metastasis of ER-positive breast cancer cells. However, context matters: in endometrial cancer, 27-HC promotes cell proliferation by activating estrogen receptors — not LXRs.

25-HC is also linked to cancer spread. It promotes cell migration and invasion in lung, gastric, and brain cancers. It does so by activating a G protein-coupled receptor, the Toll-like receptor 2 (TLR2)/NF-kB pathway, and the LXR/interleukin-1B (IL-1B) signaling pathway.

How Cancer Rewires Cholesterol Regulation

Cancer cells do not merely use cholesterol metabolism — they actively reprogram it. Internal factors (such as signaling pathway molecules or cholesterol itself) and external factors (such as the tumor microenvironment) both influence cholesterol metabolism by regulating the activity of SREBP and LXR transcription factors.

The Central Role of SREBP Activation

SREBP activation plays a central role in the abnormal cholesterol metabolism of tumor cells. When cholesterol is low, the SCAP-SREBP2 complex is sorted into COPII vesicles — tiny transport bubbles — and moved from the ER to the Golgi. There, proteolytic activation of SREBP2 is triggered. This process requires four components to work together: SCAP, S1P, S2P, and SRE. Any abnormality, such as a mutation in any one of these participants, can disrupt cholesterol metabolism.

25-HC and other oxysterols are much more effective than cholesterol itself at binding to Insig proteins. This binding promotes Insig's attachment to SCAP, which keeps the SCAP-SREBP2 complex trapped in the ER. Under sterol-deficient conditions (when cells lack these fats), Insig1 degrades. The SCAP-Insig complex dissociates, and the SREBP2 pathway activates, permitting transcription of downstream cholesterol genes.

Signaling Pathways That Drive Cholesterol Overproduction

In tumor cells, overactivation of the PI3K/AKT signaling pathway and alterations in the p53 pathway influence SREBP activity. The AKT/mTOR pathway is the most frequently studied cholesterol synthesis pathway in cancer cells.

Here is how the major pathways connect:

• AKT drives SREBP-2 activity and inhibits SREBP-2 degradation, thereby promoting expression of cholesterol synthesis-related genes.
• mTOR1 (mechanistic target of rapamycin complex 1) is an important upstream signaling molecule in AKT-induced SREBP activation. mTOR1 promotes active SREBP-2 proteins by phosphorylating lipin 1 (a protein that would otherwise enter the nucleus and suppress SREBP) and by regulating cholesterol trafficking from lysosomes to the ER.
• PTEN (a tumor suppressor gene) affects AKT and mTOR activation. When PTEN is lost or inactivated, AKT/mTOR signaling rises, driving SREBP-2-mediated target transcription.
• Mutant p53 promotes the mevalonate pathway by interacting with SREBPs and increasing SREBP activity. Mutations induce production of mevalonate-5-phosphate (MVP). MVP in turn promotes mutant p53 stabilization — a dangerous positive feedback loop that keeps both the mutant p53 and cholesterol production high.
• Normal p53 acts differently. It increases expression of the cholesterol efflux transporter ABCA1, which represses SREBP2 maturation and inhibits the mevalonate pathway.
• Androgen receptor (AR) signaling, relevant in prostate cancer, mediates SCAP upregulation and promotes SREBP activity.
• The Wnt-β-catenin pathway, activated when Cilia is repressed, promotes expression of mevalonate pathway genes through SREBP-2 interactions.

MIEF2: A New Player in Lipid Reprogramming

MIEF2 (mitochondrial elongation factor 2) is a key regulator of mitochondrial fission (the division of mitochondria, the cell's energy-producing organelles). Studies show that MIEF2 enhances lipid biosynthesis by increasing mitochondrial reactive oxygen species production. This promotes subsequent activation of the AKT/mTOR signaling pathway, which upregulates SREBP1 and SREBP2 and their transcriptional targets. Those targets include the lipogenic (fat-making) enzymes ACC1, FASN, SCD1, HMGCS1, and HMGCR. MIEF2 overexpression, through the mitochondrial dysfunction it causes, plays a key role in reprogramming lipid metabolism in ovarian cancer cells.

LXR: The Balancing Counterweight

Liver X receptors (LXRs) form obligate heterodimers with retinoid X receptors (RXRs). They regulate the expression of ABCA1 and ABCG1, the cholesterol efflux transporters. As sensors, LXRs are activated by high intracellular cholesterol content. This creates a feedback loop: when cholesterol is high, LXRs push the cell to export it.

The oncogene c-Fos disrupts this balance in hepatocytes (liver cells). c-Fos inhibits LXR signaling and increases production of cholesterol and cholesterol-derived metabolites, such as oxysterols and bile acids. These effects are associated with increased hepatocellular carcinogenesis (liver cancer formation). In normal conditions, oxysterols function as endogenous ligands (natural activating molecules) for LXRs, suppressing a transcriptional program that drives LDL uptake and promoting cholesterol efflux. This maintains cholesterol homeostasis.

Fine-Tuning at the Protein Level

Cholesterol synthesis is regulated not only at the level of gene transcription but also at the protein level. In sterol-rich environments where HMGCR transcription is inhibited, HMGCR synthesis is controlled by mevalonate derivatives. FPP and GGPP (geranylgeranyl pyrophosphate) sit downstream of mevalonate in the cholesterol synthesis pathway. When HMG-CoA reductase inhibitors (statins) deplete mevalonate, the availability of FPP and GGPP drops — affecting not only cholesterol synthesis but also the prenylation (fat tagging) of many cancer-related proteins. Cholesterol derivatives such as 25-HC also reduce the activity of HMGCR.

HMGCR itself is regulated by post-translational modifications — chemical changes made after the protein is built. These include acetylation, ubiquitination, and phosphorylation. Several E3 ubiquitin ligases (enzymes that tag proteins for destruction) lead to HMGCR degradation. The named ligases are Gp78, TRC8, HRD1, MARCHF6, and RNF145.

Specific sterols trigger this degradation, including C4-dimethylated sterols, lanosterol, and its C24-saturated derivative 24,25-dihydrolanosterol. Interestingly, cholesterol itself does not directly affect HMGCR degradation. In addition to ubiquitination, HMGCR is controlled by phosphorylation. In humans, AMPK (AMP-activated protein kinase, a cellular energy sensor) mediates phosphorylation of HMGCR at a specific site called Ser872. This phosphorylation inhibits HMGCR activity and decreases cholesterol production.

The p53 Gene: A Double Agent in Cholesterol Control

The p53 gene is one of the most famous genes in cancer research. It normally acts as a tumor suppressor — the "guardian of the genome" — that stops damaged cells from growing. When p53 is mutated, it loses that protective function and can even gain new, harmful abilities.

Cholesterol metabolism sits at the center of p53's dual role. Normal p53 increases the expression of ABCA1, the cholesterol efflux transporter. Higher ABCA1 levels push cholesterol out of the cell. This represses SREBP2 maturation and subsequently inhibits the mevalonate pathway. In this way, normal p53 keeps cholesterol production in check.

Mutant p53 (mutp53) flips the script. It promotes mevalonate pathway activation by interacting with SREBPs and increasing SREBP activity. The activated mevalonate pathway then increases levels of MVP (mevalonate-5-phosphate). MVP binds to mutant p53 and stabilizes it, protecting it from degradation. This creates a positive feedback loop: mutant p53 drives cholesterol production, and a product of that pathway keeps mutant p53 alive. The result is sustained, elevated cholesterol metabolism that feeds cancer growth.

Studies in cells and animal models reinforce this picture. Accumulation and stabilization of mature SREBP2 increases mevalonate pathway enzyme expression when p53 is absent. In prostate cancer, the loss of normal p53 function combined with androgen receptor signaling amplifies cholesterol production. These findings help explain why p53 mutation status might predict which patients respond to cholesterol-targeting therapies.

The Tumor Microenvironment: A Hostile Neighborhood

Tumors do not grow in isolation. They are surrounded by a complex environment called the tumor microenvironment (TME), containing blood vessels, immune cells, connective tissue, and chemical signals. The TME is often acidic, inflamed, and low in oxygen and nutrients. Research shows that these external conditions directly influence cholesterol metabolism in cancer cells.

Low pH (acidic conditions) promotes cholesterol biosynthesis. In pancreatic cancer cells studied at pH 6.8 — a common acidic level in tumors — low-pH-responsive genes mediate SREBP2 nuclear localization. This upregulates the expression of SREBP2 target genes, driving cholesterol production.

Hypoxic (low-oxygen) conditions and low nutrient concentrations also matter. They induce ER stress in the TME, which affects cholesterol metabolism because cholesterol is synthesized in the ER. Lipopolysaccharide (LPS), a molecule from bacterial cell walls, and the cytokine TNF (tumor necrosis factor, an inflammatory signal) both enhance cholesterol accumulation by activating SREBP2. In the liver microenvironment, hepatocyte growth factors (HGFs) activate cholesterol metabolism through the c-Met/PI3K/AKT/mTOR signaling pathways.

These findings matter because they suggest that the metabolic environment around a tumor is not passive. An acidic, inflamed microenvironment actively encourages cancer cells to build more cholesterol, which in turn helps them survive and grow.

Noncoding RNAs: Tiny Managers of Cholesterol Genes

Much of the human genome does not code for proteins. Instead, it produces noncoding RNAs (ncRNAs) — RNA molecules that regulate how other genes behave. Numerous studies show that ncRNAs affect cholesterol homeostasis by influencing cholesterol transport, uptake, and efflux. These ncRNAs play critical roles in cancer progression.

MicroRNAs (miRNAs) — small RNA molecules about 22 building blocks long — are the most studied class in this context. They work by binding to messenger RNA and preventing protein production. Many miRNAs target key cholesterol genes:

• miR-128-1 targets ABCA1 and LDLR, regulating cholesterol efflux and uptake
• miR-148a targets ABCA1 and LDLR, regulating efflux and uptake
• miR-130b targets ABCA1 and LDLR, regulating efflux and uptake
• miR-301b targets ABCA1 and LDLR, regulating efflux and uptake
• miR-185 targets SR-B1, regulating selective uptake of HDL cholesterol
• miR-96 targets SR-B1, regulating selective uptake of HDL cholesterol
• miR-223 targets SR-B1, regulating selective uptake of HDL cholesterol
• miR-24 targets SR-B1, regulating cholesterol uptake
• miR-33 targets SREBP2 and ABCA1, acting as an upstream regulator of ABCA1
• miR-183 targets ABCA1, regulating cholesterol efflux
• miR-26 targets ABCA1, regulating cholesterol efflux
• miR-20a/b targets ABCA1, regulating cholesterol efflux
• miR-758 targets ABCA1, regulating cholesterol efflux

Because these tiny RNA molecules can dial cholesterol metabolism up or down in cancer cells, they are being explored both as biomarkers (biological indicators of disease) and as potential therapeutic targets.

Clinical Implications: Targeting Cholesterol to Treat Cancer

The evidence reviewed here points to a clear conclusion: cholesterol metabolism is not a side issue in cancer — it is part of the engine that drives tumor growth. This opens the door to treatments that disrupt that engine.

Several classes of drugs target cholesterol metabolism, and many are already approved for other conditions. The most prominent are statins, which inhibit HMGCR — the rate-limiting enzyme in cholesterol synthesis. Statins are widely used for heart disease, but this review highlights their potential in cancer. By blocking HMGCR, statins deplete mevalonate and its downstream products, FPP and GGPP. These molecules are not only cholesterol building blocks; they also attach to and activate many cancer-related proteins. Reducing their availability can therefore slow cancer cell signaling and growth.

Other drug targets reviewed include:

• ACAT1 inhibitors: Blocking ACAT-1 reduces cholesteryl ester storage. Studies show this inhibits glioblastoma growth and reduces prostate cancer cell invasiveness.
• SREBP inhibitors: Because SREBP2 is the master transcription factor driving cholesterol genes, blocking its activation could broadly suppress cholesterol metabolism in tumors.
• SCAP modulators: Interfering with the SCAP-SREBP2 complex prevents SREBP2 from reaching the Golgi, where it is activated.
• PCSK9 inhibitors: PCSK9 normally induces degradation of the LDL receptor. Inhibiting PCSK9 preserves LDLR and increases cholesterol clearance from the blood. The review mentions PCSK9 in the context of LDLR degradation, an area with implications for both heart disease and cancer metabolism.
• LXR agonists: Activating LXR pushes cells to export cholesterol rather than keep it. Oxysterols such as 27-HC work through this pathway, though their effects in cancer are context-dependent — promoting metastasis in ER-positive breast cancer but acting differently in other settings.

The authors frame these approaches as a new strategy for cancer treatment. But they emphasize that cholesterol metabolism interacts with many other cancer pathways, including immune response, ferroptosis, autophagy, stemness, and DNA damage repair. The most promising future approach may be combination therapy — pairing cholesterol-targeting drugs with existing chemotherapy, immunotherapy, or radiation.

A crucial nuance emerges from the data: cholesterol's effects depend on cancer type and genetic context. ER-positive breast cancer cells respond to 27-HC through LXR activation, while endometrial cancer cells respond to the same molecule through estrogen receptors. Mutant p53 tumors behave differently from p53-normal tumors. Personalized treatment plans would need to account for these differences.

Limitations of This Review

As a review article, this paper synthesizes existing studies rather than presenting new clinical trial data. The authors note several important limitations in the research they describe.

First, most mechanistic findings come from cell culture and animal models. Whether these pathways operate identically in human patients remains to be confirmed.

Second, cholesterol metabolism is highly context-dependent. The same oxysterol can promote metastasis in one cancer type and proliferation through a different receptor in another. This complicates any one-size-fits-all treatment strategy.

Third, systemic effects matter. Cholesterol-lowering drugs act on the whole body, not just the tumor. The immune system also needs cholesterol, and manipulating cholesterol metabolism could affect immune cells' ability to fight cancer. The review notes that cholesterol regulates immune response, but the direction of that regulation is not always favorable to the patient.

Fourth, some controversial findings exist in the literature. For example, cholesterol itself does not directly trigger HMGCR degradation, but specific sterol intermediates do — a fine distinction that underscores how carefully targeted therapies must be designed.

Finally, the article is a snapshot of the field as of 2023. Rapid advances in this area mean that new targets and drugs are continuously being identified.

What This Means for Patients

This research does not mean that all cholesterol is bad, nor that patients should panic about normal cholesterol levels. Cholesterol is essential for cell health, and the body tightly regulates it. The problem in cancer is the loss of that regulation.

For patients, several practical takeaways emerge from this review:

• Statins are being studied in cancer. The review emphasizes mevalonate pathway inhibition as a plausible cancer strategy. Patients currently taking statins for heart health may wonder whether these drugs also affect cancer risk or outcomes. Clinical trials are examining this question, but patients should not change or start statins without consulting their oncology team.
• Diet and cholesterol may matter, but the mechanism is complex. The relationship between dietary cholesterol and tumor cholesterol metabolism is not straightforward, since cancer cells manufacture much of their own cholesterol from acetyl-CoA. Future research may clarify whether dietary interventions help.
• Tumor testing may guide treatment. Because p53 mutation status, cancer type, and receptor expression all influence how cholesterol pathways behave, future treatment may include genetic and molecular testing to decide who benefits from cholesterol-targeting drugs.
• This is a field in progress. Much of the evidence is from laboratory models. Patients should be cautious about unproven over-the-counter supplements claiming to target cholesterol for cancer treatment. The most reliable route is participation in clinical trials or discussion with an oncologist.

The big picture is hopeful. Cancer cells depend on cholesterol metabolism in ways that healthy cells may not. That difference — the cancer cell's increased reliance on these pathways — creates a therapeutic window. Drugs that selectively target cholesterol metabolism could weaken cancer cells while sparing normal tissue. Over the coming years, this line of research could translate into new treatment options for patients with pancreatic, breast, prostate, liver, ovarian, and other cancers.

Frequently Asked Questions

How is cholesterol connected to cancer?

Cancer cells lose normal control of cholesterol balance. They usually increase cholesterol uptake and synthesis, which helps them grow, survive, and spread. This abnormal cholesterol metabolism is now considered a hallmark of cancer, and scientists are studying drugs that target this pathway as a possible cancer treatment.

If I have cancer, should I be worried about my cholesterol levels?

Cholesterol is essential for healthy cells, and the body tightly regulates it. The problem in cancer is loss of that regulation, not simply high cholesterol. Cancer cells often make much of their own cholesterol, so dietary cholesterol levels may not directly affect tumor metabolism. Discuss any concerns with your oncology team.

Are statins being studied as cancer treatments?

Yes. Statins block HMGCR, a key enzyme in cholesterol production. In laboratory studies, this reduces availability of molecules that activate cancer-related proteins. Clinical trials are examining whether statins affect cancer outcomes, but patients should not start or change statins without consulting their oncologist.

Do cancer cells make their own cholesterol or take it from the body?

Cancer cells do both. They can build cholesterol from scratch through the mevalonate pathway, and they can import it from the bloodstream using LDL receptors or HDL receptors like SR-BI. Both processes are often increased in cancer, helping tumor cells maintain the cholesterol they need.

Are there new drugs that target cholesterol metabolism for cancer?

Several classes are being studied. Besides statins, researchers are looking at ACAT1 inhibitors, which reduce cholesterol storage and slowed tumor growth in lab models, and SREBP inhibitors, which block a master regulator of cholesterol genes. These are experimental and not yet standard cancer treatments.

How do p53 mutations affect cholesterol and cancer?

Normal p53 helps keep cholesterol production in check by promoting cholesterol efflux. Mutant p53 does the opposite: it increases cholesterol production, and a product of that pathway helps stabilize mutant p53. This creates a cycle that may support cancer growth, so p53 status might guide future treatments.

What should I do with this information about cholesterol and cancer?

Do not change or start any cholesterol medication without speaking to your oncologist. The evidence is mostly from laboratory models, and effects depend on cancer type and genetics. Ask your doctor about clinical trials that might test cholesterol-targeting therapies for your situation.

My doctor has not mentioned cholesterol-lowering drugs like statins as part of my cancer treatment. Can a second opinion tell me if this type of therapy could help my cancer?

Because cholesterol metabolism is now understood as a driving force in many cancers, and drugs like statins or ACAT1 inhibitors are being studied as cancer therapies, a second opinion can help you understand whether this emerging science applies to your specific tumor. The benefit depends on your cancer type, p53 mutation status, and receptor expression, which may predict whether cholesterol-targeting drugs could help. A second opinion can also clarify whether you are a good candidate for clinical trials of these agents, rather than relying on unproven supplements. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Functional significance of cholesterol metabolism in cancer from threat to treatment

Authors: Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Jialin Li, Hang Xu, Yingjun Zhao, Xianjun Yu, and Si Shi (Mingming Xiao, Jin Xu, and Wei Wang contributed equally).

Affiliation: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Shanghai Pancreatic Cancer Institute; Pancreatic Cancer Institute, Fudan University; and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

Journal: Experimental & Molecular Medicine (2023) 55:1982–1995. Published online September 1, 2023. Received December 4, 2022; revised May 18, 2023; accepted June 20, 2023.

DOI: https://doi.org/10.1038/s12276-023-01079-w

Corresponding authors: Xianjun Yu (yuxianjun@fudanpci.org) and Si Shi (shisi@fudanpci.org)

This patient-friendly article is based on peer-reviewed research. It has been written to make the scientific content accessible to a general audience while preserving all key findings, numbers, and conclusions from the original publication.